Increased expression of stathmin in eutopic endometrium of patients with endometriosis.

BACKGROUND: Stathmin was identified as an endometriosis-related protein by comparative proteomics in our previous study. As a microtubule-destabilizing factor, stathmin was shown to participate in the relay and integration of diverse intracellular signaling pathways involved in cell proliferation, differentiation, and many other cellular activities. To investigate whether stathmin is involved in the pathogenesis of endometriosis, we examined the expression of stathmin in eutopic endometrium of women with or without endometriosis. METHODS: Eutopic endometrium samples were collected from thirty-six patients who were diagnosed as endometriosis and the nineteen age-matched patients who were confirmed to be free of endometriosis surgically and histologically. The expression of stathmin mRNA was detected by real-time PCR, and its protein was detected by Western blotting and immunohistochemistry. RESULTS: Stathmin was overexpressed in eutopic endometrium of women with endometriosis detected by real-time PCR in mRNA levels and by Western blotting in protein levels, without significant difference between proliferative and secretory phase. Immunohistochemistry showed that stathmin protein was localized in both endometrial glandular and stromal cells throughout the menstrual cycle. CONCLUSIONS: Stathmin is overexpressed in endometrium of patients with endometriosis and may play a role in the pathogenesis of endometriosis.

[Effects of gonadotropin on the expression of growth differentiation factor 9 and 9B in mouse ovary].

OBJECTIVES: To study the effects of gonadotropin on the expression of growth differentiation factor-9 (GDF-9) and -9B (GDF-9B) in mouse ovary. METHODS: We chose follicles of mature mice cultured in vitro and mature BALB/c mice as our animal models. (1) In vivo experiment. Twenty mice were divided into two groups (groups A and B) randomly with ten mice in each group. Each mouse was injected with 10 IU pregnant mare's serum gonadotropin in group A and saline of the same volume was given to the other group. Twenty-four hours later we obtained ovarian tissue and immunohistochemistry and in situ hybridization were performed to detect the expression of GDF-9 and GDF-9B. (2) In vitro experiment. Fifty-eight separated follicles were divided into two groups (groups C and D) randomly and cultured in vitro. Thirty-two follicles in group C were cultured in medium with follicular stimulating hormone (FSH) for 72 hours while 26 were cultured without FSH. Immunohistochemistry was performed to detect the expression of GDF-9 in both groups. RESULTS: We abserved 370 follicles by immunohistochemistry. The weak positive (+ or ++) rate was 22.0% and 46.2% while the strong positive (+++ or ++++) rate was 22.6% and 9.1% in 186 follicles of group A. The weak positive (+ or ++) rate in group B was 42.4% and 42.9% while the strong positive (+++ or ++++) rate was 14.1% and 0.5%. The expression of GDF-9 was higher in group A than that of group B. The weak positive rate, positive rate and strong positive rate in group C was 28.1%, 53.1% and 18.8% while that in group D was 61.5%, 30.8% and 7.7%, respectively. The expression of GDF-9 was higher in group C than that of group D. We observed 362 follicles by in situ hybridization. The weak positive (+ or ++) rate was 31.5% and 46.2% while the strong positive (+++ or ++++) rate was 21.2% and 1.1% in 184 follicles of group A. The weak positive (+ or ++) rate in group B was 39.9% and 41.6% while the strong positive (+++ or ++++) rate was 15.7% and 2.8%. There were no differences in the expression of GDF-9B between groups A and B. CONCLUSION: Gonadotropin increases the expression of GDF-9 in vivo while FSH increases GDF-9 in vitro. Gonadotropin has no effects on the expression of GDF-9B.